The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Harbour BioMed; Merck
Research Funding - Beihai Kangcheng Beijing) Medical Technology Co., Ltd (Inst); Beijing Xiantong Biomedical Technology Co., Ltd. (Inst); Boehringer Ingelheim (Inst); Jacobio (Inst); QiLu Pharmaceutical (Inst); Zaiding Pharmaceutical Shanghai) Co., Ltd. (Inst)
Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).
 
Daniel V.T. Catenacci
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Gritstone Bio; Guardant Health; Lilly; Merck; Seagen; Taiho Pharmaceutical; Tempus
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Foundation Medicine; Genentech; Guardant Health; Lilly; Merck; Tempus
 
Minori Koshiji Rosales
Employment - MacroGenics
Stock and Other Ownership Interests - MacroGenics
 
Hyun Cheol Chung
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Amgen; Beigene; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical
 
Harry H. Yoon
Consulting or Advisory Role - ALX ONCOLOGY; Astellas Scientific and Medical Affairs Inc; BeiGene; Bristol-Myers Squibb; LSK Biopharma; Macrogenics; Merck; Zymeworks
Research Funding - Boston Biomedical (Inst); Lilly/ImClone (Inst); Merck (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Lilly
 
Lin Shen
No Relationships to Disclose
 
Markus H. Moehler
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly/ImClone; Merck Serono; MSD Oncology; Roche/Genentech; Servier; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Bayer; Lilly; Merck Serono; MSD; Nordic Group; Pfizer; Roche; SERVIER; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Jennerex (Inst); Leap Therapeutics (Inst); Merck Serono (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Amgen; ASCO; Bayer; ESMO; German Cancer Society; Merck Serono; MSD; Roche
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Novartis; Surface Oncology; Zymeworks